What happens to Celgene (CELG) if the proposed $74 billion acquisition by Bristol-Myers Squibb (BMY) dies?
“That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on its board are doing everything they can to prevent the deal from unraveling,” said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.
I reached out to Aryeh because the Bristol-Celgene deal is suddenly a bit shaky, with two big shareholders, Wellington Management and Starboard, opposing the transaction. Aryeh is well-suited to gauge the level of freak-out inside Celgene because he’s been there himself as the director of numerous biotech and drug companies. Aryeh was chairman of the Canadian drug maker QLT in 2014 when a proposed merger with another drug company blew up over a superior bid from another entity. He’s also a director at Ligand Pharmaceuticals, where he’s helped find and negotiate numerous successful acquisitions.
About the Author Reprints
why panic,though i have a fair stake in celgene,and welcome the deal,our pipeline ought to suffice for the future.If not,than what is all the hype about Bristol Myers looking toward the future via the celgene pipeline.It the deal goes south,why should Celgene given their future drug prospects.These scare tactics are just short term profit driven behaviors.